ArticleJournal of nanobiotechnology2025
Biomimetic Cu
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Biomimetic membrane-coated metal nanoplatforms for enhanced BBB penetration and targeted glioblastoma therapy.International journal of pharmaceutics: X · 2026Review
- Overcoming barriers: mechanisms and strategies of nanoparticles in overcoming the blood-brain barrier and drug resistance in glioblastomas.Journal of the Egyptian National Cancer Institute · 2026Review
- Plasma-Nanomedicine Synergistic Therapy for Brain Diseases: Current Status, Applications, and Challenges.Antioxidants (Basel, Switzerland) · 2026Review
- Multifunctional CuFrontiers in chemistry · 2026Review
- Targeting lineage-specific heterogeneity and hypovascular-fibrotic barriers may enable precision immunotherapy in pituitary neuroendocrine tumors.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Glioblastoma (GBM) is an aggressive and highly heterogeneous brain tumor that continues to pose a significant clinical challenge. Current therapeutic strategies, including surgical resection, radiotherapy, and chemotherapy, are hindered by the tumor's invasive behavior, resistance to treatment, and the difficulty of selectively targeting tumor cells. Emerging modalities, such as immunotherapy and photodynamic therapy, hold considerable promise; however, their efficacy in treating GBM is limited by critical barriers, including poor penetration of the blood-brain barrier (BBB), tumor heterogeneity, and insufficient accumulation of therapeutic agents at the tumor site. In this study, innovative biomimetic copper selenide nanoparticles (CS@CM) are developed for targeted photothermal therapy of GBM. These nanoparticles are functionalized with glioma cell membranes (CM), and this biomimetic design leverages the homing capability of the membranes to achieve efficient BBB penetration and enhanced targeting of GBM tissues. CS@CM act as potent photothermal agents upon light activation, which can amplify reactive oxygen species-induced oxidative stress to damage glioma cells. Such combination therapy effectively triggers immunogenic cell death to achieve splendid antitumor efficacy, offering a promising therapeutic strategy for GBM. Collectively, this approach addresses the limitations of conventional treatments, paving the way for improved clinical outcomes in managing this formidable malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.